Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 May 15;93(9):923-8.
doi: 10.1097/TP.0b013e31824b36fa.

Anemia after kidney transplantation; its prevalence, risk factors, and independent association with graft and patient survival: a time-varying analysis

Affiliations
Comparative Study

Anemia after kidney transplantation; its prevalence, risk factors, and independent association with graft and patient survival: a time-varying analysis

Heather Jones et al. Transplantation. .

Abstract

Introduction: Posttransplant anemia and its association with transplant outcomes have not been properly studied.

Methods: We examined 530 renal allograft recipients transplanted at our center and followed up for 31.0±14.1 months. Hemoglobin (Hb), serum bicarbonate, and creatinine; use of erythropoiesis-stimulating agent (ESA) and iron; and immunosuppressive regimen data were obtained at multiple time points during 24-month posttransplant.

Results: The overall prevalence of anemia was 89.4% at the time of transplant, dropping to 49.2% at 1 year and 44.3% at 2 years. ESA use decreased from 25.6% at 1 month to 8.23% at 24 months, only in 30.9% to 51.2% with severe anemia; 21.0% to 29.2% received iron supplements. Factors independently predictive of Hb included male gender (β=0.64, P<0.001, confidence interval [CI]: 0.45-0.82), estimated glomerular filtration rate (β=0.21 per 10 mL/min/1.73 m, P<0.001; CI: 0.16-0.27), bicarbonate (β=0.4 per 10 mmol/L increase, P<0.001; CI: 0.31-0.85), using angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (β=0.36, P<0.001; CI: 0.16-0.55), African American race (β=-0.34, P=0.001, CI:-0.54 to -0.14), iron (β=-0.28, P=0.003, CI:-0.47 to -0.09) and ESA use (β=-0.73, P<0.001, CI:-0.93 to -0.52), and prednisone (β=-0.46, P<0.001, CI:-0.71 to -0.22 for >10 mg/day vs. none). Using a competing-risk regression model, Hb less than 9 in men and less than 8 in women, was associated with 5.25-fold higher risk of death-censored graft loss compared with no anemia (adjusted, P=0.005, CI: 1.7-16.7). Degree of anemia also remained significantly associated with risk of death (hazard ratio [HR]: 2.2, P<0.1, CI: 0.9-5.6 for grade 2; HR: 3.9, P=0.009, CI: 1.4-10.8 for grade 3; and HR: 4.8, P=0.08, CI: 1.5-15.4 for grade 4, all vs. grade 0).

Conclusion: We showed that posttransplant anemia is common, and ESA/iron use remains suboptimal, and Hb is independently associated with graft failure and mortality.

PubMed Disclaimer

Publication types

MeSH terms